Mandate

Vinge advises ABGSC in connection with EQL Pharma’s inaugural bond issuance

January 24, 2025 Banking and Finance

Vinge has advised ABG Sundal Collier in connection with EQL Pharma AB (publ)’s ( “EQL”) inaugural issuance of SEK 350,000,000 senior secured bonds within a framework of up to SEK 700,000.

The bonds carry a floating interest rate of STIBOR 3M + 4.00% and have a tenor of three years. EQL intends to apply for admission to trading of the bonds on Nasdaq Transfer Market and the corporate bond list of Nasdaq Stockholm. The net proceeds from the issuance will be used to finance the acquisition of a portfolio with original pharmaceuticals, repayment of existing financial indebtedness and for general corporate purposes.

Vinge’s team consisted of Mikael Ståhl, Arvid Weimers, August Ahlin and Sara Jansson.

Related

Vinge advises Vimian in connection with new RCF and issuance of senior unsecured bonds

Vinge advises Vimian Group AB (publ) (“Vimian”) in connection with a new EUR 330 million multicurrency revolving facility agreement and its issuance of senior unsecured bonds in an amount of EUR 150 million (within a framework of EUR 250 million)
May 28, 2025

Vinge represents Alrik Technologies in connection with their latest funding round

Vinge has represented Alrik Technologies in connection with their latest funding round led by People Ventures, with Pi Labs doubling down on their investment.
May 27, 2025

Vinge advises Trinax in connection with the acquisition of Struqtur

Trinax, a Helix Kapital portfolio company, has acquired Struqtur, a Swedish company offering a comprehensive cloud-based software solution for time reporting, project management and work orders.
May 26, 2025